Role of <em>COX-2</em> Promoter Methylation and <em>Helicobacter pylori</em> Infection in Impaired Gastric Ulcer Healing by Yasuda, Hiroshi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Role of COX-2 Promoter Methylation and Helicobacter
pylori Infection in Impaired Gastric Ulcer Healing
Hiroshi Yasuda, Yoshiyuki Watanabe,
Ritsuko Oikawa and Fumio Itoh
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.79973
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
-
iroshi  asu a, oshiyuki  atanabe, 
its   i   i  It
dditional infor ation is available at the end of the chapter
Abstract
Helicobacter pylori (H. pylori) infection causes aberrant DNA methylation of various genes 
in the gastric mucosa. Cyclooxygenases (COX) play a critical role in peptic ulcer develop-
ment and healing. Human COX-2 has CpG islands (CGIs) in its promoter region, suggest-
ing a possible epigenetic regulation. Here, we evaluated COX-2 promoter methylation in 
the gastric mucosa of patients with various gastric diseases and found that COX-2 meth-
ylation levels in the gastric mucosa were significantly increased in patients with H. pylori 
infection. We further investigated the roles of COX-2 during the healing of acetic acid-
induced gastric ulcers in H. pylori-infected Mongolian gerbils (MGs). While COX-2 mRNA 
expression levels on the edges of acetic acid-induced gastric ulcers were significantly 
increased after ulcer induction in MGs in the absence of H. pylori, no such induction was 
observed in H. pylori-infected gastric mucosa. Cloning of the MG COX-2 gene revealed 
abundant CGIs in the promoter region. COX-2 mRNA expression in MG-derived gastric 
carcinoma MGC2 cells was significantly increased by addition of the demethylating agent 
5-Aza-dC. Additionally, COX-2 methylation levels were higher in H. pylori-infected MG 
gastric mucosa than in control mucosa. These results indicated that epigenetic inhibition 
of COX-2 mRNA induced by H. pylori impairs gastric ulcer healing.
Keywords: COX-2, gastric ulcer healing, Helicobacter pylori, methylation,  
Mongolian gerbils, MGC2 cells
1. Introduction
Helicobacter pylori (H. pylori) is a Gram-negative bacterium that selectively colonizes the gastric 
epithelium of humans and is the leading cause of peptic ulcers [1]. Although the majority of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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individuals infected with H. pylori remain asymptomatic throughout their life, essentially all 
infected individuals develop chronic inflammation. Patients with antral-predominant gastri-
tis are predisposed to duodenal ulcers, while patients with corpus-predominant gastritis and 
multifocal atrophy are more likely to have gastric ulcers. Eradication of H. pylori drastically 
lowers the recurrence of H. pylori-associated peptic ulcers. In addition, the observed delayed 
ulcer healing has been reported to involve H. pylori-induced inflammation, increased apoptosis 
of epithelial cells at the ulcer margin, overexpression of inflammatory cytokines, and reduced 
gastric microcirculation [2]. Cyclooxygenase (COX) is a membrane-bound glycoprotein that 
functions as the rate-limiting enzyme in prostaglandin (PG) synthesis. PGs increase the resis-
tance of the gastric mucosa to injury by downregulating inflammatory responses. Two major 
COX isoforms have been identified, COX-1, which is constitutively expressed and considered a 
housekeeping enzyme, and COX-2, whose mRNA levels rise rapidly in response to inflamma-
tory and mitogenic stimuli. There is a known synergism between H. pylori infection and non-
steroidal anti-inflammatory drug (NSAID) use in the development of peptic ulcers and ulcer 
bleeding [3]. These findings indicate possible interactions between H. pylori infection, COX 
activity, and ulcerogenesis. Aberrant methylation of 5′-CpG islands (CGIs) has been implicated 
in the transcriptional silencing of a wide range of genes involved in various diseases, such as 
cancer. Human COX-2 has CG-rich CGIs in its promoter region, which suggests epigenetic 
regulation. Here, we report and discuss our recent results on the epigenetic regulation of COX-2 
activity in H. pylori-infected gastric mucosa of humans and Mongolian gerbils (MGs), and the 
possible relationship between COX-2 methylation and delayed gastric ulcer healing.
2. COX and the gastric mucosal barrier
In 1971, Vane and colleagues first demonstrated that aspirin and other NSAIDs inhibited the 
synthesis of PGs by blocking COX activity [4]. COX plays pivotal roles in the gastric muco-
sal barrier [5, 6]. COX catalyzes the conversion of arachidonic acid to the common precur-
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of these metabolites binds to a specific G protein-coupled receptor to trigger intracellular 
responses. PGs have been shown to accelerate ulcer healing in experimental models and 
humans [7]. COX exists in two isoforms commonly referred to as COX-1 and COX-2. COX-1 
is constitutively expressed in various tissues. In the stomach, prostanoids synthesized via the 
COX-1 pathway are responsible for cytoprotection of the gastric mucosa and the production 
of thromboxane by platelets. Although COX-2 is generally expressed at very low levels in 
healthy tissues, including in the stomach, it is expressed at particularly high levels at sites of 
inflammation.
It was originally thought that only COX-1 was involved in the gastric mucosal defense system; 
however, several clinical trials have suggested that a COX-2 selective inhibitor produces lesser, 
but some, gastrointestinal toxicity compared to traditional NSAIDs [8, 9]. In accordance with 
this finding, animal studies have suggested that both COX-1 and COX-2 are necessary for gas-
tric mucosal healing, and COX-1 inhibition alone, which can be induced pharmacologically 
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by specific inhibitors or genetically by gene targeting [10], does not cause gastric mucosal 
injury. It has been shown that a combination of selective COX-1 and COX-2 inhibitors is 
required to cause hemorrhagic erosion of the gastric mucosa, which is comparable to that 
observed with indomethacin [11]. Prostanoids produced by COX-2, especially PGE
2
, enhance 
cell proliferation. The beneficial effects of PGE
2
 on gastric ulcer healing in rodents appear 
to be mediated via the EP4 receptor [12]. In addition, COX-2-derived PG stimulates vascu-
lar endothelial growth factor (VEGF) release from gastric fibroblasts, which is an important 
contributor to ulcer healing [13, 14], likely via stimulation of new blood vessel growth. The 
increase in COX-2 immunoreactivity that is observed in monocytes, macrophages, fibroblasts, 
and endothelial cells at the ulcer margin is closely correlated, both temporally and spatially, 
with the increase in cell proliferation [15]. COX-2 appears to represent a second line of defense 
that is activated during ulcer healing to compensate for the temporary loss of COX-1 in the 
mucosa adjacent to the ulcer and assists COX-1 in protecting gastric mucosal integrity. The 
healing-impairment effect of NSAIDs is also observed with selective COX-2 inhibitors [16].
3. H. pylori infection and COX-2 in gastric mucosa
The pathophysiological roles of COX-2 in H. pylori-infected gastric mucosa are intriguing. 
H. pylori has been implicated as an inducer of COX-2 in the stomach [17–19]. In addition, 
COX-2 expression is elevated within H. pylori-induced gastritis and malignant lesions [20], 
and H. pylori induced COX-2 expression and enhanced PGE
2
 production in a human gastric 
carcinoma cell line. Both H. pylori infection and NSAID use independently and significantly 
increase the risk of peptic ulcers and ulcer bleeding. While COX-2 is necessary for gastric 
mucosal healing [21], H. pylori infection is the leading cause of gastric ulceration. To under-
stand the bimodal effects of H. pylori infection on COX-2 induction during ulcer healing, we 
explored the effects of epigenetic regulation and H. pylori infection on the induction of COX-2 
in vivo and in vitro.
H. pylori infection causes aberrant DNA methylation of various genes in the gastric mucosa, 
including COX-2 [22–25]. Human COX-2 has CGIs in its promoter region. Thus, we com-
pared COX-2 promoter methylation levels in the gastric mucosa in H. pylori-positive and 
H. pylori-negative cases [26]. As mentioned above, in qualitative experiments, COX-2 gene 
promoter methylation levels were significantly higher in H. pylori-positive cases than in 
H. pylori- negative cases (Figure 1). COX-2 promoter methylation levels were significantly 
lower in patients with H. pylori eradication than in those with H. pylori infection. We then 
investigated the effects of COX-2 promoter methylation on COX-2 mRNA expression in vitro 
using the human gastric adenocarcinoma cell line Kato III, in which the COX-2 promoter is 
densely methylated [22]. COX-2 mRNA expression was not observed in these cells, despite 
the addition of the protein kinase C stimulator α-phorbol 12,13-dibutyrate (PDBu). However, 
COX-2 expression was observed after the addition of the demethylating agent 5-Aza-dC, 
and expression was enhanced by adding PDBu (Figure 2) [26]. These results indicate that H. 
pylori infection causes reversible COX-2 promoter methylation in the gastric mucosa, and that 
COX-2 mRNA expression is regulated through an epigenetic mechanism.
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Figure 2. Effects of a PKC stimulator (α-phorbol 12,13-dibutyrate; PDBu) on COX-2 mRNA expression with or without 
5-aza-dC in the human gastric adenocarcinoma cell line KATO-III. KATO-III cells were treated with vehicle (1 μmol/L) 
with or without 5-Aza-dC for 5 days. The figure is modified from Ref. [26].
Figure 1. COX-2 DNA methylation levels in patients with or without H. pylori infection, and patients previously with 
successfully eradicated H. pylori infection. The figure is modified from Ref. [26].
Chromatin and Epigenetics210
4. Acetic acid-induced gastric ulcer healing and COX mRNA levels 
in Mongolian gerbils with or without H. pylori infection
H. pylori infection in humans is best modeled in Mongolian gerbils (MGs), and chronic 
infection with H. pylori induces inflammatory cell infiltration in the gastric mucosa in MGs 
(Figure 3A). It was previously shown that H. pylori infection significantly delayed acetic 
acid-induced ulcer healing in mice and MGs [27–29]. H. pylori infection induces aberrant 
DNA methylation of several CGIs in MGs [30]. As described above, COX-2-derived PGs are 
important for gastric ulcer healing, and the COX-2 promoter is densely methylated in the 
human gastric mucosa in the presence of H. pylori infection. To investigate the roles of COX-2 
Figure 3. A. Microscopic features of H. pylori-infected gastric mucosa of Mongolian gerbils (MGs). Sections were stained 
with hematoxylin and eosin. B. Gross appearance 10 days after gastric ulcer induction of H. pylori-infected MGs. 
C. Microphotograph 10 days after gastric ulcer induction in H. pylori-infected MGs. D. Serial changes in acetic acid-
induced gastric ulcer areas in MGs with or without H. pylori infection. H. pylori (ATCC43504; American Type Culture 
Collection, Rockville, MD) was grown in Brucella broth (Becton Dickinson, Cockeysville, MD) containing 10% v/v horse 
serum for 40 h at 37°C under microaerobic conditions (15% CO
2
) and high humidity with shaking (150 rpm). Male MGs 
(MGs/Sea) were purchased from Kyudo (Saga, Japan). At 11 weeks of age, H. pylori (0.8 mL samples of Brucella broth 
containing 1.0 × 109 colony-forming units) was delivered intragastrically using an oral catheter after fasting for 24 h. 
Gastric ulcers were induced experimentally in MGs according to the method described by Wang et al. [40]. Briefly, 
after anesthetization with ketalar, the abdomen was opened through a midline incision, and 50 μL of 25% acetic acid 
was injected in the subserosa of the anterior wall of the stomach. The MGs were killed at5, 10, and 20 days after ulcer 
induction, and the stomach was dissected and removed. The maximum and minimum diameters of the ulcers were 
measured, and the ulcer area, which was approximately elliptical, was calculated and was compared between MGs 
with and without H. pylori infection. Values are the mean ± SE. The animal care committee of St. Marianna University 
approved the experimental design, and the animals were cared for in accordance with institutional guidelines.
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methylation and H. pylori infection in gastric ulcer healing, COX mRNA levels in samples 
prepared from acetic acid-induced gastric ulcers in MGs were examined. Then, the effects 
of COX-2 methylation on COX-2 mRNA expression were also investigated in vitro using an 
H. pylori-infected MG stomach-derived cell line.
Gastric ulcers were produced by injecting 25% of acetic acid (0.03 mL) into the submucosal 
layer of the gastric wall of the antral-oxyntic border in MGs 48 weeks after inoculation with 
an H. pylori suspension in Brucella broth. The MGs were killed at 5, 10, and 20 days after 
ulcer induction, and the stomachs were dissected and removed. The maximum and minimum 
diameters of the ulcers were measured, and the area of each ulcer, which was approximately 
elliptical, was calculated and compared between MGs with and without H. pylori infection. 
The ulcer area was largest on day 5, and then gradually decreased. In accordance with previ-
ous reports [29], the gastric ulcer area was larger in H. pylori-infected MGs than in uninfected 
MGs (Figure 3B–D). While COX-2 mRNA expression at the ulcer edge was increased 5 days 
after acetic acid injection in MGs without H. pylori infection, as was reported in rats and mice 
[31], no increases in COX-2 mRNA levels were observed in H. pylori-infected MGs. In contrast, 
gastric ulceration was not associated with a change in COX-1 mRNA levels in MGs with or 
without H. pylori infection (Figure 4A,B). Thus, H. pylori infection caused delayed ulcer heal-
ing and impaired COX-2 induction in MG stomachs.
Figure 4. COX mRNA levels during healing of an acetic acid-induced gastric ulcer in MGs with or without H. pylori 
infection. COX mRNA levels in acetic-acid-induced gastric ulcers in MGs were measured by real-time PCR. First-strand 
cDNA was prepared by reverse transcription of 5 μg of total RNA using superscript III reverse transcriptase (Applied 
Biosystems, Carlsbad, CA, USA). Real-time quantitative reverse transcription PCR was carried out using TaqMan Gene 
Expression Assays with a 7500 real-time PCR system (Applied Biosystems) according to the manufacturer’s instructions. 
Primers for COX-1, COX-2, and β-actin were designed based on their cDNA sequences (GenBank accession nos. AB 
044783, AB044784, and AB040445, respectively) and according to previous reports [33]. SDS2.1 software (Applied 
Biosystems) was used to perform the comparative Δ-Ct analysis. Glyceraldehyde-3-phosphate dehydrogenase was 
used as an endogenous control. Values are the mean ± SE. β-Actin left: gctacagcttcaccaccaca, right: ccatctcttgctcgaagtcc, 
93 bp. COX-1 left: gtggctatttcctgcagctc, right: agtgggtgccagtggtagag, 112 bp. COX-2 left: tgggcgtgaaaggaaataag, right: 
ggggatcagggatgaacttt, 87 bp.
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5. Effects of COX-2 methylation on its mRNA expression in MGs  
in vitro
As discussed above, COX-2 mRNA expression is regulated by an epigenetic mechanism 
in KATO-III human gastric carcinoma cells in which COX-2 is densely methylated [22]. To 
investigate the role of methylation in COX-2 mRNA expression in H. pylori-infected gastric 
mucosa of MGs, we treated MGC2 cells with 5-aza-dC, a methyltransferase inhibitor, or 
trichostatin A (TSA), a histone deacetylase inhibitor. MGC2 is an adenocarcinoma cell line 
established from the gastric cancer tissue of a H. pylori-infected MG [32]. COX-2 mRNA 
expression levels in these cells were restored after the addition of 5-aza-dC. In contrast, 
treatment with TSA did not induce COX-2 mRNA expression (Figure 5). These results 
indicated that COX-2 mRNA expression in MGs is regulated via both transcriptional and 
epigenetic mechanisms. Histone acetylation was not involved in silencing COX-2 expression 
in these cells.
6. Cloning the MG COX-2 promoter region
As mentioned above, human COX-2 has abundant CGIs in the promoter region. To examine 
whether CGIs are present in the COX-2 promoter region of MGs, we performed genomic 
Figure 5. Effects of 5-aza-dC, a methyltransferase inhibitor, or trichostatin A (TSA), a histone deacetylase inhibitor, on 
COX-2 mRNA expression in MG gastric adenocarcinoma MGC2 cells. The MGC2 cells [32] were a generous gift from 
Dr. Tatematsu and were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; Gibco, 
Grand Island, NY, USA) plus serum expander MITO (0.1%, Collaborative Biomedical Products Bedford, MA, USA) on 
a type I collagen-coated dish (Asahi Techno Glass, Japan). All the cultures were incubated at 37°C with 95% air and 
5% CO
2
. COX-2 mRNA expression was measured by real-time PCR in the cell lines grown in the presence of vehicle with 
or without 5-Aza-dC (1 μmol/L) or TSA for 5 days. Values shown are the mean ± SE.
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PCR with primers designed using as previously reported MG cDNA (Accession #: AB177842) 
[33]. The PCR product has an intron sequence in the promoter region. Then, gene walking 
was performed using a primer in this intron. The promoter region of the MG COX-2 gene 
was obtained (Figure 6), and the sequence contains more CGIs than the mouse genome, and 
Figure 6. Human, MG, and mouse COX-2 promoter regions. Genome walking to isolate genomic, the COX-2 promoter 
region of MGs, was performed by using the Straight Walk Kit [41] according to the manufacturer’s instructions 
(Bex, Tokyo, Japan). Amplified fragments were cloned into the pSTBlue-1 vector (Novagen, Madison, WI, USA) and 
sequenced. More abundant CGIs were observed in the MG genome when compared to the mouse genome, and the 
number was comparable to human genome.
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is comparable to that of the human genome. Pyrosequencing showed several methylated 
CGIs (>15%) in the MGC2 cells. Treatment with 5-aza-dC decreased the methylation levels 
in these cells (Figure 7). As was observed in the human stomach, COX-2 methylation levels 
were increased in H. pylori-infected gastric mucosa of MGs when compared to the levels in 
the control mucosa (Figure 8).
Figure 7. Effect of 5-aza-dC treatment on COX-2 methylation levels in MGC2 cells. Cells were treated with vehicle (A) 
with 5-aza-dC (B, 1 μmol/L) for 5 days, and then methylation levels of COX-2 were analyzed by quantitative bisulfite-
pyrosequencing methods as previously reported [42]. Bisulfite treatment of gDNA was performed with the EpiTect 
bisulfite kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s protocol. Bisulfite-treated DNA (1 μL) was 
used as a template in subsequent PCR experiments. For most assays, we used touchdown PCR. All PCR assays included 
a denaturation step at 95°C for 30 s, followed by annealing at various temperatures for 30 s, and extension at 72°C for 30 s. 
After PCR, the biotinylated strand was captured on streptavidin-coated beads (Amersham Bioscience, Uppsala, Sweden) 
and incubated with sequencing primers. Pyrosequencing was performed using PSQ HS 96 Gold single-nucleotide 
polymorphism reagents on a PyroMark Q24 pyrosequencing machine (QIAGEN). The protocol for pyrosequencing 
was described in detail previously [42]. Pyrosequencing quantitatively measures the methylation status of CpG sites in 
a target region. Adjacent sites usually show highly concordant methylation. Therefore, the mean percent methylation in 
detected sites can be used as a representative value for each gene promoter. Cases with the methylation density > 15% 
were regarded as methylation positive. Forward primer: tgggtgaggggaattttataga, reverse primer: aaaccctaaccatccttacaa; 
and sequencing primer: aggagtttgtttaggaag.
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7. Role of COX-2 methylation and H. pylori infection in gastric 
mucosal healing
Nonselective COX inhibitors damage the gastrointestinal mucosa, and gastrointestinal 
injury represents the most significant side effect of chronic nonsteroidal anti-inflammatory 
drug (NSAID) use [34]. Thus, selective COX-2 inhibitors have been developed as ideal anti- 
inflammatory drugs, devoid of GI toxicity, and clinical trials have suggested that selective 
COX-2 inhibitors produce less gastrointestinal injury than conventional NSAIDs [8, 9]. In 
support of this, animal studies have also suggested that, in contrast to the initial concept, the 
importance of COX-2 in the repair of gastric mucosal damage has been recognized [31, 35]. In 
rat gastric mucosa, markedly elevated levels of COX-2 mRNA were observed after induction 
of damage by ischemia-reperfusion [35, 36]. COX-2 mRNA and protein expression increase 
during repair of gastric mucosal lesions, and selective COX-2 inhibitors delay mucosal heal-
ing in mice [31]. PGs derived from ulceration-induced COX-2 at the ulcer margin enhanced 
epithelial cell proliferation and increased the expression of growth factors, including hepato-
cyte growth factor, epidermal growth factor, transforming growth factor-α, and VEGF [16].
The release of inflammatory cytokines and recruitment of inflammatory cells have been con-
sidered the potential factors for delayed ulcer healing in H. pylori infection [2, 28]. Chronic 
inflammation, including H. pylori infection, is known to cause aberrant DNA methylation 
[37, 38]. Here, we focused on COX-2 methylation in H. pylori-infected gastric mucosa. Human 
COX-2 has CGIs in the promoter region, and methylation levels in this region are increased in 
Figure 8. DNA methylation levels at COX-2 in the MG gastric mucosa in the presence or absences of H. pylori infection. 
Methylation levels at COX-2 in the MG gastric mucosa were analyzed by quantitative bisulfite pyrosequencing.
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H. pylori-infected gastric mucosa. In addition, COX-2 promoter methylation levels in patients 
with successfully eradicated H. pylori infection are lower than the levels in H. pylori-positive 
cases. As mentioned above, experiments using rodents have shown that COX-2 mRNA 
expression is enhanced during ulcer healing. Thus, we investigated the influence of H. pylori 
infection on COX-2 expression during stomach ulcer healing in MGs. Acetic acid-induced 
ulcer healing was delayed in H. pylori-infected MG stomachs when compared to the healing of 
ulcers without H. pylori infection [29]. The COX-2 promoter region of MGs also has abundant 
CGIs, comparable to human COX-2. Thus, MGs are good models for investigating the role of 
COX-2 methylation in gastric mucosal healing. While COX-2 mRNA expression at the ulcer 
edge was increased 5 days after acetic acid injection in MG stomachs without H. pylori infec-
tion, as was observed in the mouse and rat models, such increases in COX-2 mRNA expres-
sion were not observed in H. pylori-infected MG gastric mucosa. However, a demethylating 
agent restored COX-2 mRNA expression in both human and MG gastric carcinoma cell lines 
in which COX-2 is densely methylated. Accordingly, we demonstrated in vitro and in vivo that 
COX-2 mRNA expression is regulated through an epigenetic mechanism in human and MG 
gastric mucosa. Aberrant DNA methylation has been extensively investigated in the context 
of the pathogenesis of various cancers, including stomach cancer. In addition, the involve-
ment of epigenetic modifications has been reported in the pathogenesis of various chronic 
diseases, such as essential hypertension and cardiovascular disease [39]. Taken together, the 
epigenetic inhibition of COX-2 expression due to chronic inflammation induced by H. pylori 
infection seems to interfere with ulcer healing and increase the vulnerability of the gastric 
mucosa. The decrease in COX-2 methylation levels after H. pylori eradication may restore 
gastric mucosal defense.
8. Conclusions
H. pylori infection, the leading cause of peptic ulcer disease, induces sustained inflammation 
in the gastric mucosa. This chronic inflammation causes aberrant DNA methylation in various 
genes. The COX-2 promoter regions in both MGs and humans contain abundant CGIs. COX 
plays critical roles in peptic ulcer development and healing, and both COX-1 and COX-2 
are necessary for the gastric mucosal defense system. COX-1 is a housekeeping enzyme, 
which maintains microcirculation and mucous production. During ulcer healing, COX-2 is 
expressed at the margin of an ulcer, and COX-2-derived PGs induce various growth factors to 
promote mucosal healing and angiogenesis. Ulcer healing is delayed in H. pylori infected-MG 
stomachs, which is the best model of H. pylori infection in humans. We showed that  COX-2 
mRNA induction during ulcer healing was impaired in H. pylori-infected-MG stomachs. 
The  COX-2 promoter region is methylated in both H. pylori-infected human and MG gastric 
mucosa. These CGIs are also methylated in human Kato III cells and MGC2 gastric carcinoma 
cells. COX-2 mRNA expression in these cells is restored by treatment with a demethylat-
ing agent. In H. pylori-infected gastric mucosa, COX-2 promoter methylation appears to be 
involved in the impaired COX-2 mRNA induction typically observed during ulcer healing, 
which leads to delayed ulcer healing.
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